Dali apheresis in hyperlipidemic patients: Biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood

Artificial Organs

Volumn 24, Issue 2, 2000, Pages 81-90

  Bosch, T ^a,b   Lennertz, A ^a   Schmidt, B ^a   Fink, E ^a   Keller, C ^b   Toepfer, M ^c   Drager J ^d   Samtleben, W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Dialysis Center   (Germany)

^d UNIVERSITY OF APPLIED SCIENCES STRALSUND   (Germany)

Author keywords

Biocompatibility; Bradykinin; Direct adsorption of lipoproteins; LDL; LDL Hemoperfusion; Lipoprotein(a); Pheresis

Indexed keywords

BIOCOMPATIBILITY; BLOOD; CHEMICAL ACTIVATION; CHOLESTEROL; LIPOPROTEINS; PATIENT TREATMENT;

BLOOD VOLUMES; BRADYKININ; DIRECT ADSORPTION OF LIPOPROTEIN; HEMOPERFUSION; LIPOPROTEIN(A); LOW DENSITY LIPOPROTEINS; LOW- DENSITY LIPOPROTEIN-HEMOPERFUSION; PHERESIS; WHOLE BLOOD;

ADSORPTION;

ADSORPTION; ADULT; AGED; APHERESIS; ARTICLE; BIOCOMPATIBILITY; CLINICAL ARTICLE; FEMALE; GERMANY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL;

EID: 0034122623     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.2000.06476.x     Document Type: Article

References (29)

1. 1. Bosch T. Lipid apheresis: From a heroic treatment to clinical routine practice. Artif Organs 1996;20:414-9.
2. 2. Gordon BR, Saal SD. Current status of LDL-apheresis for the therapy of severe hyperlipidemia. Current Opinion Lipidology 1996;7:381-4.
3. 3. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
4. 4. Ballantyne CM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto AM. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Current Opinion Lipidology 1997;8:354-61.
5. 5. Bosch T. State of the art of lipid apheresis. Artif Organs 1996; 20:292-5.
6. 6. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: In vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993;17: 640-52.
7. 7. Bosch T, Schmidt B, Kleophas W, Gillen C, Otto V, Paßlick-Deetjen J, Gurland HJ. LDL-hemoperfusion - a new procedure for LDL-apheresis: First clinical application of an LDL-adsorber compatible with human whole blood. Artif Organs 1997;21:977-82.
8. 8. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W. LDL-hemoperfusion - a new procedure for LDL-apheresis: Biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif Organs 1997;21: 1060-5.
9. 9. Shimamoto K, Ando T, Tanaka S, Iimura O. The determination of kinin and glandular kallikrein in human biological fluids. Atemwegs-Lungenkrankheiten 1988;1(Suppl 14):29-36.
10. 10. Fink E, Schill WB, Fiedler F, Krassnigg F, Geiger R, Shimamoto K. Tissue kallikrein of human seminal plasma is secreted by the prostate gland. Biol Chem Hoppe-Seyler 1985; 366:917-24.
11. 11. Kaiser RE, Mühlbauer JA. Elementare Tests zur Beurteilung von Meßdaten. Soforthilfe für statistische Tests mit wenigen Meßdaten, 2nd ed. Mannheim: Bibliographisches Institut, 1983.
12. 12. Heidland AH, Hörl WH, Heller H, Heine H, Neumann S, Heidbreder E. Proteolytic enzymes and catabolism: Enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis. Kidney Int 1983;24(Suppl 16):S27-36.
13. 13. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Thrombogenicity markers in clinical and ex vivo assessment of membrane biocompatibility. In: Koch KM, Streicher E, eds. Biological reactions within the extracorporeal blood circuit during hemodialysis. Contributions to Nephrology, vol. 59. Basel: Karger, 1987:90-8.
14. 14. Pereira BJG, Dinarello CA. Production of cytokines and inhibitory proteins in patients on dialysis. Nephrol Dial Transplant 1994;9(Suppl 2):60-71.
15. 15. Cheung AK. Complement activation as indices of haemodialysis membrane haemocompatibility: The choice of methods and assays. Nephrol Dial Transplant 1994;9(Suppl 2):96-103.
16. 16. Lindhout T. Biocompatibility of extracorporeal blood treatment. Selection of haemostatic parameters. Nephrol Dial Transplant 1994;9(Suppl 2):83-9.
17. 17. Persson E, Nordenström J, Nilsson-Ehle P, Hagenfeldt L. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur J Clin Investigation 1985;15:215-20.
18. 18. Yamamoto A, Kojima S, Shiba-Harada M, Kawaguchi A, Hatanaka K. Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose columns. Artif Organs 1992;16:177-81.
19. 19. Richter WO, Sühler K, Schwandt P. Extracorporeal LDL elimination by immunoadsorption: Side effects and influences on other serum lipoproteins and serum parameters. In: Gotto AM Jr, Mancini M, Richter WO, Schwandt P, eds. Treatment of severe hypercholesterolemia in the prevention of coronary heart disease, vol. 2. Basel: Karger, 1990:183-7.
20. 20. Jaeger BR, Meiser B, Nagel D, Überfuhr P, Thiery J, Brandl U, Brückner W, von Scheidt W, Kreuzer E, Steinbeck G, Reichart B, Seidel D. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation 1997;96(Suppl II):II-154-8.
21. 21. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Int Med 1993;118:956-63.
22. 22. Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981;67:223-8.
23. 23. Blumenstein M, Schmidt B, Bosch T, Habersetzer R, Heigl F, Gurland HJ. Heparin versus citrate in membrane plasma filtration. In: Nosé Y, Kjellstrand C, Ivanovich P, eds. Progress in artificial organs - 1985. Cleveland: ISAO Press, 1986:821-6.
24. 24. Bosch T, Schmidt B, Samtleben W, Gurland HJ. New LDL-adsorption column containing dextran sulfate: Ex vivo clinical performance and biocompatibility. In: Oda T, Shiokawa Y, Inoue N, eds. Therapeutic apheresis (VI). Cleveland: ISAO Press, 1987:576-80.
25. 25. Johnson RJ. Complement activation during extracorporeal therapy: Biochemistry, cell biology, and clinical relevance. Nephrol Dial Transplant 1994;9(Suppl 2):36-45.
26. 26. Keller C, Grützmacher P, Bahr F, Schwarzbeck A, Kroon AA, Kiral A. LDL-apheresis with dextran sulfate and anaphylactoid reactions to ACE inhibitors. Lancet 1993;341:60-1.
27. 27. Tielemans C, Madhoun P, Lenaers M, Schandene L, Goldman M, Vanherwegheim JL. Anaphylactoid reactions during hemodialysis on AN 69 membranes in patients receiving ACE inhibitors. Kidney Int 1990;38:982-4.
28. 28. Kojima S, Ogi M, Yoshitomi Y, Kuramochi M, Ikeda J, Naganawa M, Hatakeyama H. Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis. Int J Artif Organs 1997;20:178-83.
29. 29. Dräger LJ, Julius U, Kränzle K, Schaper J, Toepfer M, Zygan K, Otto V, Steinhagen-Thiessen E. DALI - the first human whole-blood LDL and Lp(a) apheresis system in clinical use: Procedure and clinical results. Eur J Clin Invest 1998;28: 994-1002.